Rodman & Renshaw Downgrades CollaGenex (CGPI) to Market Perform
More News related to CGPI
- CollaGenex Pharmaceuticals (CGPI) Reports Q4 EPS of $0.02
- Caxton Associates Discloses 6.1% Stake in CollaGenex (CGPI)
- Roth Capital Downgrades CollaGenex (CGPI) to Hold
- Wachovia Downgrades CollaGenex (CGPI) to Market Perform
- Rodman & Renshaw Downgrades CollaGenex (CGPI) to Market Perform
Rodman & Renshaw downgrades CollaGenex Pharmaceuticals (Nasdaq: CGPI) from Outperform to Market Perform and removes its $19 price target.
The firm said shares of CollaGenex will trade at or around a price of $16.60, which is the tender bid offered by Galderma Pharma yesterday before the market opened.
CollaGenex Pharmaceuticals, Inc., a specialty pharmaceutical company, develops and markets proprietary medical therapies to the dermatology market.
Related Categories
DowngradesStocks Mentioned
+0.00Sign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
